Neuralstem (CUR) Announces Presentation of NSI-189 Preclinical Data at RRS Annual Meeting
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/18/2024
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- ICZOOM Group (IZM) Discloses Request to Withdraw Registration Statement on Form F-1
- Alaska Airlines flights resume after being grounded over aircraft system issue
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Neuralstem Presents NSI-189 Preclinical Neurocognitive Benefits at the Radiation Research Society Annual Meeting
October 20, 2016 7:52 AM EDTGERMANTOWN, Md., Oct. 20, 2016 (GLOBE NEWSWIRE) -- Neuralstem, Inc. (Nasdaq: CUR), a biopharmaceutical company focused on the development of central nervous system therapies based on its neural stem cell technology, announced the presentation of the poster entitled, Reversal of radiation-induced cognitive impairment by oral administration of a neurogenic small molecule compound NSI-189, at the Radiation Research Society Annual Meeting on October 19th. The preclinical study data concluded that NSI-189 provided treatment benefits in the reversal of radiation-induced cognitive deficits.
Research led by Charles Limoli, Ph.D. at University of California, Irvine,... More
